Developer docs
API playgroundTry for free, no card

Search company profiles

T3 Pharmaceuticals

Full company profile

uuid0002g5k

Namestring
T3 Pharmaceuticals
Legal namestring
T3 Pharmaceuticals AG
Websiteurl
t3pharma.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

T3 Pharmaceuticals AG is a clinical-stage Swiss biotechnology company founded in May 2015 and based in Allschwil (Basel), Switzerland. The company has developed a proprietary bacterial delivery platform based on an engineered, attenuated strain of Yersinia enterocolitica that exploits the bacterium's natural Type III Secretion (T3S) system to deliver therapeutic proteins directly into solid tumor cells. By selectively colonizing tumor tissue and injecting immune-modulating payloads (e.g., cytokines, antibodies, T-cell engagers) into the tumor microenvironment, the platform aims to convert immunologically cold tumors into hot, inflamed ones that respond to systemic therapy.

The company's lead clinical candidate, T3P-Y058-739, entered a first-in-human Phase I dose-escalation trial in patients with advanced solid tumors and is designed to deliver a therapeutic protein payload via the T3S mechanism. The company operated as a venture-backed R&D organization, raising approximately CHF 40 million across three financing rounds between 2016 and 2020 from investors including BIVF, Reference Capital SA, and Wille Finance AG, supplemented by non-dilutive grants from Gebert Rüf Stiftung and the Innosuisse Swiss Accelerator program. Scientific founders are affiliated with the University of Basel Biozentrum, and the Scientific Advisory Board includes researchers with direct expertise in the T3S system.

T3 Pharmaceuticals was acquired by Boehringer Ingelheim in November 2023 in a transaction valued at up to CHF 450 million (upfront plus milestone payments), integrating the platform into BI's immuno-oncology R&D portfolio. As a pre-revenue clinical-stage biotech, the company had no commercial product, no product pricing model, and no go-to-market channel at the time of acquisition. The business model was venture-funded R&D progression toward either an out-licensing event, partnership, or trade sale, with the BI acquisition representing the realized exit pathway. Post-acquisition, the company operates as a BI subsidiary with the platform now funded through corporate R&D budgets rather than external capital markets.

Short descriptiontext

T3 Pharmaceuticals AG is a clinical-stage Swiss biotech developing engineered Yersinia enterocolitica-based bacterial therapies that deliver immune-modulating proteins into solid tumors via the Type III Secretion system. The company was acquired by Boehringer Ingelheim in November 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bacterial cancer therapy, immuno-oncology therapeutics, live biotherapeutic products, tumor-targeted protein delivery, solid tumor treatment
Industry1 code
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Acquisition proceeds (up to CHF 450 million)
TypeLicensing Royalties
Description

Privately-held company acquired by Boehringer Ingelheim in November 2023 for up to CHF 450 million; pre-acquisition revenue derived from non-dilutive grants and milestone-based R&D collaboration rather than commercial product sales.

t3pharma.com
2Non-dilutive grants and accelerator funding
TypeManaged Services
Description

Pre-commercial revenue derived from grants including Innosuisse Swiss Accelerator (CHF 2.5 million, 2023), Gebert Rüf Stiftung (CHF 400,000 over two years, 2017), BaseLaunch accelerator funding, CTI/KTI, and the W.A. de Vigier Foundation prize (CHF 100,000, 2019).

t3pharma.com
3Venture / private equity financing rounds
TypeTransaction Fee
Description

Capital raised through multiple venture rounds: first financing round (2016, private Swiss investors), second round >CHF 12M (2019), third round >CHF 25M (2020, total cumulative CHF 40M).

t3pharma.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

T3 Pharmaceuticals develops a proprietary live-bacterial immuno-oncology platform that uses engineered Yersinia enterocolitica bacteria to selectively colonize solid tumors and act as nano-syringes via the bacterial type III secretion (T3S) system to deliver chosen immune-modulating proteins into tumor cells. The company's lead candidate, T3P-Y058-739, is the first therapeutic product from this platform and was in a Phase I clinical trial for solid tumors at the time of the company's acquisition by Boehringer Ingelheim.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

T3 Pharmaceuticals AG offers a single proprietary technology platform (the T3S Protein Delivery Platform) built on the bacterial type III secretion system, from which it has developed a focused pipeline of bacteria-based immuno-oncology therapies for solid tumors. Its sole named clinical-stage product is the lead asset T3P-Y058-739, which is the first therapeutic candidate generated by the platform and was undergoing a Phase I clinical trial at the time of the company's acquisition by Boehringer Ingelheim in November 2023. The platform and lead program are tightly integrated: the platform provides the engineered Yersinia enterocolitica bacterial vehicle and intracellular protein-delivery mechanism, while T3P-Y058-739 represents the first product instantiation designed to induce a tumor-selective immune response within solid tumors.

Product and service2 records
1T3P-Y058-739
CategoryLead clinical-stage product
Description

T3 Pharma's lead immuno-oncology therapeutic candidate, designed to induce a highly specific immune response selectively within solid tumors. It is the first therapeutic candidate built on T3 Pharma's proprietary type III secretion (T3S) protein delivery platform using engineered Yersinia enterocolitica bacteria, and was being tested in a Phase I clinical trial in solid tumors at the time of the company's acquisition by Boehringer Ingelheim.

2T3S Protein Delivery Platform
CategoryProprietary technology platform
Description

Proprietary cancer therapy platform built by repurposing the bacterial type III secretion (T3S) system. Genetically engineered Yersinia enterocolitica bacteria selectively colonize solid tumors (via removal of key virulence factors) and act as nano-syringe delivery vehicles, injecting chosen bioactive proteins into tumor cells to trigger immune responses such as immune cell activation or cell death. The platform is versatile and can be loaded with multiple immune-modulatory proteins to enable immuno-oncology combination therapies in a single agent.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing Clostridium novyi-NT spores that selectively colonize hypoxic regions of solid tumors — the closest mechanistic analog to T3 Pharma's tumor-selective live-bacterial cancer therapy platform. Both target solid tumors using engineered bacteria with intrinsic tumor tropism.

2AntiCancer Inc
TypeDirect peer
Description

Pioneer of bacteria-based cancer therapy approaches (notably Salmonella typhimurium and obligate anaerobes) for solid tumors. Pioneered by Dr. Zheng Cui, AntiCancer Inc is one of the few commercial-stage entities pursuing bacteria-mediated tumor killing, directly comparable to T3 Pharma's modality.

TypeEmerging player
Description

Clinical-stage Norwegian biotech developing oncolytic antimicrobial peptides for solid tumors — same philosophy of using biological agents to selectively disrupt tumor cells and stimulate immune response, though mechanistically distinct from T3's bacterial delivery approach.

TypeEmerging player
Description

Clinical-stage biotech developing engineered oncolytic vaccinia viruses (e.g., GL-ONC1) that selectively replicate in and lyse solid tumor cells — a comparable 'biological vehicle for tumor-selective payload delivery' strategy that competes with T3 Pharma in the immuno-oncology niche.

TypeEmerging player
Description

Formerly PsiOxus Therapeutics; clinical-stage company developing engineered oncolytic adenoviruses (NG-348, NG-641) that deliver immune-modulating payloads into solid tumors — directly comparable to T3 Pharma's T3S platform in concept, differing only in viral vs. bacterial delivery vehicle.

TypeEmerging player
Description

Clinical-stage European biotech developing viral cancer immunotherapies and off-the-shelf neoantigen vaccines for solid tumors. Comparable to T3 Pharma as a Basel-adjacent European clinical-stage immuno-oncology player using engineered biological vehicles for tumor-selective payload delivery.

7Turnstone Biologics
TypeEmerging player
Description

Clinical-stage biotech developing oncolytic viral immunotherapies and tumor-infiltrating lymphocyte (TIL) therapies for solid tumors — overlapping with T3 Pharma's immuno-oncology focus on solid tumors using biologically engineered payloads.

8Istari Oncology
TypeEmerging player
Description

Clinical-stage biotech developing PVSRIPO, a polio-rhinovirus chimera, for solid tumors including glioblastoma and melanoma — comparable to T3 Pharma as a tumor-selective biological immunotherapeutic modality targeting solid tumors.

TypeEmerging player
Description

Clinical-stage biotech developing VB-111 (ofranergene obadenovec), an oncolytic virus-based gene therapy for solid tumors. Comparable to T3 Pharma as a late-stage clinical immuno-oncology asset using engineered biological vectors to deliver anti-cancer payloads.

10Boehringer Ingelheim
TypeBroad incumbent
Description

Now the parent company of T3 Pharma, Boehringer Ingelheim operates a broad immuno-oncology portfolio spanning T-cell engagers, oncolytic viruses, and cancer vaccines. Relevant as the broad incumbent integrating T3's bacterial delivery platform into a wider I-O franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

T3 Pharmaceuticals

Immuno-Oncology Biopharmaceuticalst3pharma.com

T3 Pharmaceuticals AG is a clinical-stage Swiss biotech developing engineered Yersinia enterocolitica-based bacterial therapies that deliver immune-modulating proteins into solid tumors via the Type III Secretion system. The company was acquired by Boehringer Ingelheim in November 2023.

What T3 Pharmaceuticals does

T3 Pharmaceuticals AG is a clinical-stage Swiss biotechnology company founded in May 2015 and based in Allschwil (Basel), Switzerland. The company has developed a proprietary bacterial delivery platform based on an engineered, attenuated strain of Yersinia enterocolitica that exploits the bacterium's natural Type III Secretion (T3S) system to deliver therapeutic proteins directly into solid tumor cells. By selectively colonizing tumor tissue and injecting immune-modulating payloads (e.g., cytokines, antibodies, T-cell engagers) into the tumor microenvironment, the platform aims to convert immunologically cold tumors into hot, inflamed ones that respond to systemic therapy.

The company's lead clinical candidate, T3P-Y058-739, entered a first-in-human Phase I dose-escalation trial in patients with advanced solid tumors and is designed to deliver a therapeutic protein payload via the T3S mechanism. The company operated as a venture-backed R&D organization, raising approximately CHF 40 million across three financing rounds between 2016 and 2020 from investors including BIVF, Reference Capital SA, and Wille Finance AG, supplemented by non-dilutive grants from Gebert Rüf Stiftung and the Innosuisse Swiss Accelerator program. Scientific founders are affiliated with the University of Basel Biozentrum, and the Scientific Advisory Board includes researchers with direct expertise in the T3S system.

T3 Pharmaceuticals was acquired by Boehringer Ingelheim in November 2023 in a transaction valued at up to CHF 450 million (upfront plus milestone payments), integrating the platform into BI's immuno-oncology R&D portfolio. As a pre-revenue clinical-stage biotech, the company had no commercial product, no product pricing model, and no go-to-market channel at the time of acquisition. The business model was venture-funded R&D progression toward either an out-licensing event, partnership, or trade sale, with the BI acquisition representing the realized exit pathway. Post-acquisition, the company operates as a BI subsidiary with the platform now funded through corporate R&D budgets rather than external capital markets.

T3 Pharmaceuticals firmographics

Firmographics
Name
T3 Pharmaceuticals
Legal name
T3 Pharmaceuticals AG
Website
https://t3pharma.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
T3 Pharmaceuticals AG is a clinical-stage Swiss biotech developing engineered Yersinia enterocolitica-based bacterial therapies that deliver immune-modulating proteins into solid tumors via the Type III Secretion system. The company was acquired by Boehringer Ingelheim in November 2023.
Ownership category
akta.pro rank

T3 Pharmaceuticals industry classification

Industry
Product category
Immuno-Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Bacterial cancer therapy
  • Immuno-oncology therapeutics
  • Live biotherapeutic products
  • Tumor-targeted protein delivery
  • Solid tumor treatment

Where T3 Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Markets served

T3 Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Acquisition proceeds (up to CHF 450 million): Privately-held company acquired by Boehringer Ingelheim in November 2023 for up to CHF 450 million; pre-acquisition revenue derived from non-dilutive grants and milestone-based R&D collaboration rather than commercial product sales.
  2. Non-dilutive grants and accelerator funding: Pre-commercial revenue derived from grants including Innosuisse Swiss Accelerator (CHF 2.5 million, 2023), Gebert Rüf Stiftung (CHF 400,000 over two years, 2017), BaseLaunch accelerator funding, CTI/KTI, and the W.A. de Vigier Foundation prize (CHF 100,000, 2019).
  3. Venture / private equity financing rounds: Capital raised through multiple venture rounds: first financing round (2016, private Swiss investors), second round >CHF 12M (2019), third round >CHF 25M (2020, total cumulative CHF 40M).

Go-to-market motion1 record

T3 Pharmaceuticals product offering

Product offering

Core offering

T3 Pharmaceuticals develops a proprietary live-bacterial immuno-oncology platform that uses engineered Yersinia enterocolitica bacteria to selectively colonize solid tumors and act as nano-syringes via the bacterial type III secretion (T3S) system to deliver chosen immune-modulating proteins into tumor cells. The company's lead candidate, T3P-Y058-739, is the first therapeutic product from this platform and was in a Phase I clinical trial for solid tumors at the time of the company's acquisition by Boehringer Ingelheim.

Product overview

T3 Pharmaceuticals AG offers a single proprietary technology platform (the T3S Protein Delivery Platform) built on the bacterial type III secretion system, from which it has developed a focused pipeline of bacteria-based immuno-oncology therapies for solid tumors. Its sole named clinical-stage product is the lead asset T3P-Y058-739, which is the first therapeutic candidate generated by the platform and was undergoing a Phase I clinical trial at the time of the company's acquisition by Boehringer Ingelheim in November 2023. The platform and lead program are tightly integrated: the platform provides the engineered Yersinia enterocolitica bacterial vehicle and intracellular protein-delivery mechanism, while T3P-Y058-739 represents the first product instantiation designed to induce a tumor-selective immune response within solid tumors.

Differentiator

Problem solved

Functional benefit

Products and services

  • T3P-Y058-739 T3 Pharma's lead immuno-oncology therapeutic candidate, designed to induce a highly specific immune response selectively within solid tumors. It is the first therapeutic candidate built on T3 Pharma's proprietary type III secretion (T3S) protein delivery platform using engineered Yersinia enterocolitica bacteria, and was being tested in a Phase I clinical trial in solid tumors at the time of the company's acquisition by Boehringer Ingelheim.
  • T3S Protein Delivery Platform Proprietary cancer therapy platform built by repurposing the bacterial type III secretion (T3S) system. Genetically engineered Yersinia enterocolitica bacteria selectively colonize solid tumors (via removal of key virulence factors) and act as nano-syringe delivery vehicles, injecting chosen bioactive proteins into tumor cells to trigger immune responses such as immune cell activation or cell death. The platform is versatile and can be loaded with multiple immune-modulatory proteins to enable immuno-oncology combination therapies in a single agent.

Companies that use T3 Pharmaceuticals

Customer profile

Ideal customer profiles1 record

T3 Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

T3 Pharmaceuticals partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights4 records

T3 Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • BioMed Valley Discoveries: Clinical-stage biotech developing Clostridium novyi-NT spores that selectively colonize hypoxic regions of solid tumors — the closest mechanistic analog to T3 Pharma's tumor-selective live-bacterial cancer therapy platform. Both target solid tumors using engineered bacteria with intrinsic tumor tropism.
  • AntiCancer Inc: Pioneer of bacteria-based cancer therapy approaches (notably Salmonella typhimurium and obligate anaerobes) for solid tumors. Pioneered by Dr. Zheng Cui, AntiCancer Inc is one of the few commercial-stage entities pursuing bacteria-mediated tumor killing, directly comparable to T3 Pharma's modality.

Emerging players

  • Lytix Biopharma: Clinical-stage Norwegian biotech developing oncolytic antimicrobial peptides for solid tumors — same philosophy of using biological agents to selectively disrupt tumor cells and stimulate immune response, though mechanistically distinct from T3's bacterial delivery approach.
  • Genelux Corporation: Clinical-stage biotech developing engineered oncolytic vaccinia viruses (e.g., GL-ONC1) that selectively replicate in and lyse solid tumor cells — a comparable 'biological vehicle for tumor-selective payload delivery' strategy that competes with T3 Pharma in the immuno-oncology niche.
  • Akamis Bio: Formerly PsiOxus Therapeutics; clinical-stage company developing engineered oncolytic adenoviruses (NG-348, NG-641) that deliver immune-modulating payloads into solid tumors — directly comparable to T3 Pharma's T3S platform in concept, differing only in viral vs. bacterial delivery vehicle.
  • Nouscom: Clinical-stage European biotech developing viral cancer immunotherapies and off-the-shelf neoantigen vaccines for solid tumors. Comparable to T3 Pharma as a Basel-adjacent European clinical-stage immuno-oncology player using engineered biological vehicles for tumor-selective payload delivery.
  • Turnstone Biologics: Clinical-stage biotech developing oncolytic viral immunotherapies and tumor-infiltrating lymphocyte (TIL) therapies for solid tumors — overlapping with T3 Pharma's immuno-oncology focus on solid tumors using biologically engineered payloads.
  • Istari Oncology: Clinical-stage biotech developing PVSRIPO, a polio-rhinovirus chimera, for solid tumors including glioblastoma and melanoma — comparable to T3 Pharma as a tumor-selective biological immunotherapeutic modality targeting solid tumors.
  • VBL Therapeutics: Clinical-stage biotech developing VB-111 (ofranergene obadenovec), an oncolytic virus-based gene therapy for solid tumors. Comparable to T3 Pharma as a late-stage clinical immuno-oncology asset using engineered biological vectors to deliver anti-cancer payloads.

Broad incumbents

  • Boehringer Ingelheim: Now the parent company of T3 Pharma, Boehringer Ingelheim operates a broad immuno-oncology portfolio spanning T-cell engagers, oncolytic viruses, and cancer vaccines. Relevant as the broad incumbent integrating T3's bacterial delivery platform into a wider I-O franchise.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

T3 Pharmaceuticals social profiles

Digital presence

T3 Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

T3 Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

T3 Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

T3 Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

T3 Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T3 Pharmaceuticals

What does T3 Pharmaceuticals do?

T3 Pharmaceuticals develops a proprietary live-bacterial immuno-oncology platform that uses engineered Yersinia enterocolitica bacteria to selectively colonize solid tumors and act as nano-syringes via the bacterial type III secretion (T3S) system to deliver chosen immune-modulating proteins into tumor cells. The company's lead candidate, T3P-Y058-739, is the first therapeutic product from this platform and was in a Phase I clinical trial for solid tumors at the time of the company's acquisition by Boehringer Ingelheim.

Is T3 Pharmaceuticals a public or private company?

T3 Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was T3 Pharmaceuticals founded?

T3 Pharmaceuticals was founded in 2015. It employs 11 to 50 people.

Where is T3 Pharmaceuticals based?

T3 Pharmaceuticals is headquartered in Basel, Switzerland, in the Europe region.

How does T3 Pharmaceuticals make money?

Three revenue lines are on record. Acquisition proceeds (up to CHF 450 million) is the primary driver. The others are non-dilutive grants and accelerator funding and venture / private equity financing rounds.

Who are T3 Pharmaceuticals's main competitors?

Direct peers on record are BioMed Valley Discoveries and AntiCancer Inc. Emerging players are Lytix Biopharma, Genelux Corporation, Akamis Bio, Nouscom, Turnstone Biologics, Istari Oncology and VBL Therapeutics. Boehringer Ingelheim is listed as a broad incumbent.

Does T3 Pharmaceuticals have an API?

No public API is recorded for T3 Pharmaceuticals.

What industry is T3 Pharmaceuticals in?

T3 Pharmaceuticals's product category is Immuno-Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechADCs, TCEs among ‘exciting things’ on Boehringer’s dealmaking shopping listBoehringer Ingelheim has been aggressively pursuing licensing deals in early 2026, signing agreements worth up to $1.26 billion with companies including Variant Bio, Rectify Pharmaceuticals, Simcere, and Sitryx for cardiorenal, kidney, inflammatory bowel disease, and autoimmune disease programs. The German pharma company, which spent €7.4 billion on R&D last year (22.9% of sales), is prioritizing T-cell engagers and antibody-drug conjugates as key pipeline expansion areas, with its DLL3/DC3 TCE obrixtamig currently in Phase 3 for small-cell lung cancer. Boehringer is awaiting Phase 3 obesity data for survodutide, its GLP-1/glucagon agonist partnered with Zealand Pharma, after mid-stage trials showed nearly 19% weight loss and significant improvement in metabolic dysfunction-associated steatohepatitis (MASH).FmiblogPet Cancer Therapeutics Market Forecast Analysis: 2034The global pet cancer therapeutics market is projected to grow from USD 400.9 million in 2024 to USD 898.6 million by 2034, a CAGR of 8.4%. Growth is driven by rising pet cancer incidence and increased awareness, with key acquisitions including Boehringer Ingelheim's purchase of T3 Pharmaceuticals and Zoetis's acquisition of Adivo.Pharmaceutical TechnologyBoehringer Ingelheim acquires T3 Pharma for $509m - Pharmaceutical TechnologyBoehringer Ingelheim has acquired T3 Pharma, a bacterial cancer therapy specialist, in a deal valued at up to $509 million. The acquisition aims to enhance Boehringer Ingelheim's immuno-oncology capabilities by incorporating T3 Pharma's technology, which allows for targeted delivery of treatments to tumor cells. T3 Pharma will continue operations in its Basel, Switzerland headquarters.FinSMEsT3 Pharma Raises CHF25M in Third FundingT3 Pharmaceuticals raised over 25M CHF in its third financing round, co-led by existing investors. The Basel-based biotech's total funding since 2015 now stands at 40M CHF. The funds will advance its lead candidate T3P-Y058-739, with a Phase 1/2 study planned for early 2021.UnquoteBIVF et al. back CHF 25m round for T3 PharmaceuticalsT3 Pharmaceuticals raised a CHF 25m round from existing investors including BIVF, Reference Capital, and Wille Finance. The funds will support its main clinical candidate T3P-Y058-739, with phase-I and phase-II studies in solid tumours expected to begin in early 2021.startupticker.chTech startups awarded the CTI LabelFour technology startups—Battrion, Perspective Robotics, FeedbackNow, and T3 Pharmaceuticals—received the CTI Label, a certification of maturity and market readiness. The label is awarded by the CTI Start-up Label Certification Board, and each startup's technology is described, including battery fabrication, drones, customer feedback, and cancer treatment.